Joseph Lyon - Corcept Therapeutics Chief Officer
| CORT Stock | USD 57.68 0.92 1.57% |
Insider
Joseph Lyon is Chief Officer of Corcept Therapeutics Incorporated
| Age | 46 |
| Address | 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 |
| Phone | 650 327 3270 |
| Web | https://www.corcept.com |
Joseph Lyon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Lyon against Corcept Therapeutics stock is an integral part of due diligence when investing in Corcept Therapeutics. Joseph Lyon insider activity provides valuable insight into whether Corcept Therapeutics is net buyers or sellers over its current business cycle. Note, Corcept Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Corcept Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Lyon over six months ago Disposition of 5443 shares by Joseph Lyon of Corcept Therapeutics at 26.0011 subject to Rule 16b-3 |
Corcept Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.13 % which means that it generated a profit of $0.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2577 %, meaning that it created $0.2577 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 652.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 349.7 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Keith MBA | Keros Therapeutics | 54 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Joanna Siegall | Cytokinetics | N/A | |
| ShinSan Su | Agios Pharm | 68 | |
| Susanna MBA | Dyne Therapeutics | 56 | |
| Craig MD | Agios Pharm | 71 | |
| Michel MD | MeiraGTx Holdings PLC | N/A | |
| Thomas Templeman | Nuvation Bio | 60 | |
| FACC MD | Cytokinetics | 58 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| T Washburn | Agios Pharm | 42 | |
| Esq JD | Ideaya Biosciences | 52 | |
| CPA CPA | NextCure | 61 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| FAAD MBA | AnaptysBio | 47 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Robert MD | Sensei Biotherapeutics | 58 | |
| Cecilia Jones | Agios Pharm | 49 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 |
Corcept Therapeutics Leadership Team
Elected by the shareholders, the Corcept Therapeutics' board of directors comprises two types of representatives: Corcept Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corcept. The board's role is to monitor Corcept Therapeutics' management team and ensure that shareholders' interests are well served. Corcept Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corcept Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hazel Hunt, Chief Officer | ||
| Amy Flood, Chief Officer | ||
| Joseph MD, President, CoFounder | ||
| William PharmD, Chief Officer | ||
| Roberto Vieira, President Oncology | ||
| Gary JD, Chief Secretary | ||
| Gary Robb, CFO, Chief Accounting Officer and Secretary | ||
| Joseph Lyon, Chief Officer | ||
| Monica Tellado, President Markets | ||
| Atabak Mokari, CFO Treasurer | ||
| Sean Maduck, Senior Vice President - Commercial |
Corcept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corcept Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 5.67 B | ||||
| Shares Outstanding | 104.78 M | ||||
| Shares Owned By Insiders | 11.51 % | ||||
| Shares Owned By Institutions | 85.53 % | ||||
| Number Of Shares Shorted | 18.34 M | ||||
| Price To Earning | 30.07 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.